Good MorningEquity markets advanced on Tuesday, putting the S&P 500 at an all-time closing high. The move signals the market's willingness to continue the uptrend and may be a precursor to much higher price points. With earnings growth expected in 2025 and the potential for economic tailwinds to form by mid-year, the S&P 500 could sustain a rally through the end of 2025.
The stock rally is broadening. New highs in the Dow Jones Industrial Average, the Transportation Average, and the Russell 200 foreshadowed the move in the S&P. The move into other areas of the economy and small caps is a good sign but spells bad news for the previous market leaders. Names like NVIDIA, Amazon, Meta Platforms, and Microsoft may have difficulty setting new highs until sometime next year when sector rotation is completed. Featured: Elon’s big $266,000 per second purchase (Ad) 
|
Medical | | Semler Scientific, Inc. (NASDAQ: SMLR) has been one of November’s hottest stocks, soaring over 130% as investors rally behind its newfound embrace of Bitcoin. The healthcare and medical devices company recently made waves by significantly expanding its Bitcoin holdings and introducing "Bitcoin... Read the Full Story |
|
From Our Partners | | Bill Poulos is offering his Smart Trade Options Checklist at no cost today - normally priced at $29.97.
It's a single-page, seven-point filter designed to help traders identify weak setups before placing any options trade. Print it, keep it at your desk, and run it before every trade. The download link expires soon. | | Download your free copy of the Smart Trade Options Checklist now |
|
Technology | |
Cerence (NASDAQ: CRNC) is an AI stock that has burst onto the radar of many investors lately. Since its latest earnings release on Nov. 21, shares have skyrocketed 155% as of the Nov. 25 close. So, what does this company do, and why am I mentioning it in the same breath as the lauded SoundHound AI... Read the Full Story |
|
Markets | |
When the biggest minds on Wall Street decide to make a significant move in their portfolios, retail investors better pay attention and attempt to reverse engineer the thinking and reasoning behind these moves. Today, investors can look at the recent 13-F filings from the Oracle of Omaha himself, W... Read the Full Story |
|
From Our Partners | | Trump is launching a new $250 bill - but that may be a distraction. Behind the scenes, Executive Order 14241 is orchestrating what analyst Porter Stansberry calls a total U.S. money reset, bypassing conventional legal channels under the guise of national security.
The last time America reset its currency - under Nixon in the 1970s - it created an average of 1,300 new millionaires a day for over 50 years. Stansberry has identified three asset categories connected to Trump's initiative that could surge, plus his single top investment move. | | Watch the documentary briefing and find out which side you land on |
|
Retail/Wholesale | |
Shares of Amazon.com, Inc. (NASDAQ: AMZN) have been having a standout year, with the stock building on the 150% rally that started in 2023. Though its shares have softened slightly in recent weeks, the tech titan was hitting fresh all-time highs just earlier this month. Even with this pullback, ... Read the Full Story |
|
Retail/Wholesale | | There are many reasons to own a stock, and the CEO is one of them. The right CEO can be the defining factor in a company’s success, shaping operations, driving growth, and delivering substantial shareholder returns. Strong leadership often signals not just steady performance but transformative... Read the Full Story |
|
From Our Partners | | Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now.
Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen.
Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch. | | Watch how to access the legal backdoor before it closes. |
|
Retail/Wholesale | |
Numerous stock buyback or repurchase authorization announcements were made throughout 2024. For the most part, they have become commonplace. A buyback authorization is not an obligation or requirement to buy back stock but more so permission to repurchase shares. The company has the option to buy ... Read the Full Story |
|
Manufacturing | |
Pure Storage Inc. (NYSE: PSTG) is a leading enterprise data storage provider specializing in all-flash storage solutions using solid-state drives (SSDs). Their FlashArray is designed for low latency, scalable and reliable storage for applications requiring high-speed access to massive datasets l... Read the Full Story |
|
Markets | |
The spot price of gold has climbed by more than a third in the last year, repeatedly reaching all-time records in the last several months. Leading up to the November election—and amid a protracted period of investor uncertainty surrounding inflation and other concerns, as well as anticipatio... Read the Full Story |
|
Retail/Wholesale | |
As the United States gross domestic product (GDP) figures for the quarter recently suggested that the American consumer was mostly responsible for carrying economic growth, investors might wonder whether it is still worth it to look into buying some retail stocks in the cyclical space, or whether ... Read the Full Story |
|
Finance | |
After a few months of weakening data, home sales reports finally ticked higher, giving investors new hope for a rebound in the real estate sector. However, there is no reason to start celebrating yet, as other factors and themes need to fall back into line before the skies are clear for the indust... Read the Full Story |
|
Wednesday's Early Bird Stock Of The Day AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. | Should I Buy AbbVie Stock? ABBV Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of AbbVie was last updated on Wednesday, July 15, 2026 at 6:07 PM.
AbbVie Bull Case -
The current stock price is around $225, which reflects a stable position in the market.
-
AbbVie recently reported earnings per share of $2.65, exceeding analysts' expectations, indicating strong financial performance.
-
The company has shown a year-over-year revenue increase of 12.4%, suggesting growth potential and effective business strategies.
-
AbbVie announced a quarterly dividend of $1.73 per share, providing a reliable income stream for investors, with an annualized yield of 2.8%.
-
The firm has a P/E ratio of 122.17, which, while high, can indicate strong future growth expectations from investors.
AbbVie Bear Case -
AbbVie has a negative return on equity of 576.45%, which may raise concerns about the company's efficiency in generating profits from shareholders' equity.
-
The dividend payout ratio is currently at 340.89%, suggesting that the company is paying out more in dividends than it earns, which could be unsustainable.
-
The stock has a beta of 0.30, indicating lower volatility compared to the market, which may limit potential high returns for aggressive investors.
-
Despite recent revenue growth, the net margin of 5.79% is relatively low, which could indicate challenges in managing costs effectively.
-
AbbVie operates in a highly competitive biopharmaceutical market, which may pose risks to its market share and profitability in the future.
| | View Today's Stock Pick |
|
